Your browser doesn't support javascript.
Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.
Palazzuoli, Alberto; Mancone, Massimo; De Ferrari, Gaetano M; Forleo, Giovanni; Secco, Gioel G; Ruocco, Gaetano M; D'Ascenzo, Fabrizio; Monticone, Silvia; Paggi, Anita; Vicenzi, Marco; Palazzo, Anna G; Landolina, Maurizio; Taravelli, Erika; Tavazzi, Guido; Blasi, Francesco; Infusino, Fabio; Fedele, Francesco; De Rosa, Francesco G; Emmett, Michael; Schussler, Jeffrey M; Tecson, Kristen M; McCullough, Peter A.
  • Palazzuoli A; Cardiovascular Diseases Unit Department of Medical Sciences AOUS Le Scotte Hospital University of Siena Italy.
  • Mancone M; Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences Sapienza, University of Rome Italy.
  • De Ferrari GM; Cardiology Department of Medical Science, University of Turin Città della Salute e Della Scienza Le Molinette Hospital Torino Torino Italy.
  • Forleo G; Section Head Electrophysiology and Cardiac Pacing Azienda Ospedaliera - Polo Universitario - "Luigi Sacco" Milano Italy.
  • Secco GG; Interventional Cardiology and Cardiac Surgery Unit Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo Alessandria Italy.
  • Ruocco GM; Cardiology Division Regina Montis Regalis Hospital Mondovì Cuneo Italy.
  • D'Ascenzo F; Cardiology Department of Medical Science, University of Turin Città della Salute e Della Scienza Le Molinette Hospital Torino Torino Italy.
  • Monticone S; Division of Internal Medicine Department of Medical Sciences University of Turin Italy.
  • Paggi A; Interventional Cardiology Department of Internal Medicine ASSST Nord Milano E Bassini Hospital Cisanello Balsamo Milan Italy.
  • Vicenzi M; Cardiovascular Disease Unit Department of Internal Medicine Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico University of Milano Italy.
  • Palazzo AG; Infectious Disease Department of Medical Sciences AOU Città Della Salute e Della Scienza University of Torino Italy.
  • Landolina M; Cardiology Division Ospedale Maggiore of Crema Italy.
  • Taravelli E; Cardiology Division Ospedale Maggiore of Crema Italy.
  • Tavazzi G; Intensive Care Fondation IRCCS Policlinico San Matteo University of Pavia Italy.
  • Blasi F; Respiratory Unit and Adult Cystic Fibrosis Center Department of Internal Medicine Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico University of Milano Italy.
  • Infusino F; Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences Sapienza, University of Rome Italy.
  • Fedele F; Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences Sapienza, University of Rome Italy.
  • De Rosa FG; Infectious Disease Department of Medical Sciences AOU Città Della Salute e Della Scienza University of Torino Italy.
  • Emmett M; Baylor University Medical Center Dallas TX.
  • Schussler JM; Baylor University Medical Center Dallas TX.
  • Tecson KM; Baylor Scott and White Heart and Vascular Hospital Dallas TX.
  • McCullough PA; Baylor Heart and Vascular Institute Dallas TX.
J Am Heart Assoc ; 9(22): e017364, 2020 11 17.
Artículo en Inglés | MEDLINE | ID: covidwho-2064368
ABSTRACT
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes the angiotensin-converting enzyme-2 (ACE-2) receptor to enter human cells. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor antagonists (ARB) are associated with ACE-2 upregulation. We hypothesized that antecedent use of ACEI/ARB may be associated with mortality in coronavirus disease 2019 (COVID-19). Methods and Results We used the Coracle registry, which contains data of patients hospitalized with COVID-19 in 4 regions of Italy, and restricted analyses to those ≥50 years of age. The primary outcome was in-hospital mortality. Among these 781 patients, 133 (17.0%) used an ARB and 171 (21.9%) used an ACEI. While neither sex nor smoking status differed by user groups, patients on ACEI/ARB were older and more likely to have hypertension, diabetes mellitus, and congestive heart failure. The overall mortality rate was 15.1% (118/781) and increased with age (PTrend<0.0001). The crude odds ratios (ORs) for death for ACEI users and ARB users were 0.98, 95% CI, 0.60-1.60, P=0.9333, and 1.13, 95% CI, 0.67-1.91, P=0.6385, respectively. After adjusting for age, hypertension, diabetes mellitus, and congestive heart failure, antecedent ACEI administration was associated with reduced mortality (OR, 0.55; 95% CI, 0.31-0.98, P=0.0436); a similar, but weaker trend was observed for ARB administration (OR, 0.58; 95% CI, 0.32-1.07, P=0.0796). Conclusions In those aged ≥50 years hospitalized with COVID-19, antecedent use of ACEI was independently associated with reduced risk of inpatient death. Our findings suggest a protective role of renin-angiotensin-aldosterone system inhibition in patients with high cardiovascular risk affected by COVID-19.
Asunto(s)
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Inhibidores de la Enzima Convertidora de Angiotensina / Antagonistas de Receptores de Angiotensina / COVID-19 / Hospitalización Tipo de estudio: Estudios diagnósticos / Estudio experimental / Estudio observacional / Estudio pronóstico / Ensayo controlado aleatorizado Límite: Anciano / Femenino / Humanos / Masculino / Middle aged País/Región como asunto: Europa Idioma: Inglés Revista: J Am Heart Assoc Año: 2020 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Inhibidores de la Enzima Convertidora de Angiotensina / Antagonistas de Receptores de Angiotensina / COVID-19 / Hospitalización Tipo de estudio: Estudios diagnósticos / Estudio experimental / Estudio observacional / Estudio pronóstico / Ensayo controlado aleatorizado Límite: Anciano / Femenino / Humanos / Masculino / Middle aged País/Región como asunto: Europa Idioma: Inglés Revista: J Am Heart Assoc Año: 2020 Tipo del documento: Artículo